LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · IEX Real-Time Price · USD
16.35
-0.18 (-1.09%)
May 17, 2024, 4:00 PM EDT - Market closed
Company Description
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States.
Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia.
The company is headquartered in Del Mar, California.
LENZ Therapeutics, Inc.
| Country | Canada |
| Founded | 2019 |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Evert B. Schimmelpennink |
Contact Details
Address: 445 Marine View Ave Suite 320 Del Mar, California 92014 United States | |
| Phone | 858-925-7000 |
Stock Details
| Ticker Symbol | LENZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| IPO Price | $17.00 |
| CIK Code | 0001815776 |
| ISIN Number | US52635N1037 |
| Employer ID | 84-4867570 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Evert B. Schimmelpennink | President, Chief Executive Officer, Secretary and Director |
| Shawn Olsson | Chief Commercial Officer |
| Marc G. Odrich M.D. | Chief Medical Officer |
| James W. McCollum | Co-Founder and Director |
| Gerald Horn | Senior Scientific Advisor and Founder |
| Daniel R. Chevallard CPA | Chief Financial Officer |
| Domenick Porfidia | Vice President of Sales |
| David Murphy | Senior Director of Marketing and Alliance Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2024 | 424B3 | Prospectus |
| May 8, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | 8-K | Current Report |
| Apr 11, 2024 | 424B3 | Prospectus |
| Apr 10, 2024 | EFFECT | Notice of Effectiveness |
| Apr 9, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 3, 2024 | UPLOAD | Filing |
| Apr 3, 2024 | 8-K | Current Report |
| Mar 29, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |